Dihexa for Burnout Brain Fog: Chronic Work Stress, Cortisol, Cognition & the 2026 UK Review

"I'm so burned out I can't think straight" has become one of the defining complaints of working life — and the 2026 numbers explain why. The UK's Health and Safety Executive reported that 964,000 workers experienced work-related stress, depression or anxiety in 2024/25 — a record — costing an estimated 22.1 million working days. The Mental Health UK Burnout Report 2026 found 91% of adults experienced high or extreme pressure in the past year. Burnout reliably fogs cognition: a 2021 meta-analysis found clinical burnout impairs executive function, attention and memory, and chronic stress is known to lower BDNF, suppress hippocampal neurogenesis and thin out synapses — the very synapse-building that Dihexa, an HGF/c-Met synaptogenic peptide, is designed to drive. This 2026 UK review walks through the biology, separates the popular "high cortisol" story from the messier reality, and explains where Dihexa actually sits — which is a long way behind rest, recovery and reducing the load, not in front of them.

Burnout and Brain Fog in 2026: A Workforce-Sized Problem

Few health complaints have spread through working life as quickly as burnout, and the 2026 data make the scale impossible to ignore. The UK's Health and Safety Executive reported that, in 2024/25, an estimated 964,000 workers in Great Britain suffered from work-related stress, depression or anxiety — the highest figure on record, accounting for 52% of all work-related ill health and an estimated 22.1 million working days lost. That is more than double the rate when records began in 2001/02, and the increase has accelerated since the pandemic.

The Mental Health UK Burnout Report 2026 fills in the human picture. Drawing on YouGov polling of more than 4,500 UK adults, it found that 91% experienced high or extreme pressure or stress at some point in the previous year, that one in five (20%) took time off work because of stress-related poor mental health — rising to 39% among 18–24-year-olds — and that the leading workplace driver was a high or increased workload (42%), with regularly working unpaid overtime (33%) and fears over redundancy and job security (32%) close behind. Outside work, poor sleep (59%) and money worries (48%) topped the list. The report also warned that recovery is poorly supported: 27% of those who took time off received no support on returning, and only 17% had a formal return-to-work plan — a finding that matters directly to burnout’s tendency to relapse.

The symptom that drives people to search the internet, though, is the cognitive one. “Burnout brain fog” means re-reading the same email five times, losing the thread mid-sentence, forgetting why you walked into a room, and being unable to hold a simple plan in working memory. It overlaps heavily with the fog produced by poor sleep, low mood, anxiety, the menopause and thyroid problems — which is part of why it is so often mislabelled. This review takes the cognitive complaint seriously, traces it down to the synapse, and asks the question that brings readers here: if chronic stress thins out synapses, could a synapse-building peptide put them back?

What Burnout Actually Is: The WHO ICD-11 Definition

Before reaching for biology, it is worth being precise about what burnout is — because the definition itself shapes the right response. In 2019 the World Health Organization included burnout in the 11th revision of the International Classification of Diseases (ICD-11), describing it as “a syndrome conceptualized as resulting from chronic workplace stress that has not been successfully managed.” Crucially, the WHO classifies it as an occupational phenomenon — a reason people contact health services — and explicitly not as a medical condition.

The WHO defines burnout by three dimensions: feelings of energy depletion or exhaustion; increased mental distance from one's job, or feelings of negativism or cynicism about it; and reduced professional efficacy. The WHO is also clear that the term refers specifically to the occupational context and should not be used for experiences in other areas of life. That framing matters enormously for the Dihexa question, because it locates the cause squarely in a situation — chronic, unmanaged workplace stress — rather than in a brain that has run out of some molecule.

This is the cleanest distinction between burnout and a disease. A virus, an autoimmune process or a neurodegenerative condition happens to the body and may need pharmacology. Burnout, by definition, arises from a mismatch between demands and recovery; resolve the mismatch and the syndrome typically resolves. That is why every credible burnout framework — clinical, occupational and psychological — centres on changing the load and restoring recovery, and why the idea of treating it with a research chemical sits awkwardly with what burnout fundamentally is.

The Cognitive Fingerprint of Burnout: What the Evidence Shows

For a long time, “brain fog” from burnout was dismissed as subjective. The evidence no longer allows that. A 2021 systematic review and meta-analysis in Work & Stress pooled studies of clinical burnout and found small-to-moderate impairments across multiple domains: executive function, attention, episodic memory, short-term and working memory, processing speed and verbal fluency. In plain terms, the parts of cognition that let you plan, focus, juggle information and find your words are exactly the parts burnout degrades.

The picture extends to non-clinical burnout too. A study of cognitive functioning, sleep quality and work performance found that people with non-clinical burnout performed significantly worse on tests of working memory — particularly the visuospatial sketchpad and the central executive — and that this tracked with poorer work performance. More recently, a 2025 resting-state EEG study in Frontiers in Human Neuroscience reported altered functional connectivity in burnout, including reduced alpha-band connectivity associated with externally oriented attention — a signature also seen in mild cognitive impairment and other conditions.

Two honest caveats keep this in proportion. First, the effect sizes are generally modest, not the profound deficits of dementia. Second, causality runs both ways: it is not fully resolved whether burnout erodes cognition, or whether people with already-stretched cognitive resources are more prone to burning out — probably some of both. What is not in doubt is that burnout-related cognitive symptoms are genuine, measurable and worth respecting — and, importantly, the literature treats them as recoverable rather than as fixed damage.

Is It Burnout, Depression, ME/CFS or Something Else?

One reason burnout fog is so often mishandled is that it sits in a crowded diagnostic neighbourhood. Its symptoms overlap substantially with depression (low mood, anhedonia, fatigue, poor concentration), and the two frequently co-exist — which is why our review of Dihexa for depression and low mood is essential companion reading. They are not identical: burnout is, by definition, tied to work and characterised by cynicism and depletion specifically around the job, whereas depression pervades all of life. But the boundary is blurry, and untreated depression is far too important to miss behind a label of “just burnout.”

The fog of burnout also overlaps with chronic anxiety and stress, with the post-exertional exhaustion of ME/CFS, and with long COVID — all of which can look like “I'm exhausted and can't think.” And it shares ground with the entirely treatable medical drivers of fog that should always be ruled out: thyroid dysfunction (see Hashimoto's and thyroid brain fog), vitamin B12 and iron deficiency, the menopause, sleep disorders such as sleep apnoea, and poorly controlled blood sugar.

The practical message is the same one that runs through this whole site: name the cause before treating the symptom. A GP assessment that distinguishes burnout from depression, checks the obvious bloods, and screens for sleep and thyroid problems will do more for burnout fog than any nootropic — and it is the step that should come before anyone even thinks about an experimental peptide.

The Cortisol Story — and Why It Is Not Simply “High Cortisol”

The internet's favourite explanation for burnout fog is “high cortisol.” It is half-right, and the half it gets wrong matters. The stress hormone cortisol is produced by the hypothalamic–pituitary–adrenal (HPA) axis, and acute stress genuinely raises it. In the short term, a cortisol surge sharpens attention. The problem is what happens when the stressor never switches off.

Under chronic stress the HPA axis becomes dysregulated rather than simply “high.” A narrative review of the endocrine and immunological aspects of burnout in the European Journal of Endocrinology describes a mixed and often counter-intuitive picture: many people with established burnout show blunted cortisol responses to stress, a flattened daily cortisol rhythm, and in some cases lower-than-normal cortisol (hypocortisolism), alongside raised inflammatory markers. One study found burnout was linked to reduced HPA-axis responsiveness, more pronounced in men. The reviews are candid that the data are heterogeneous and no single HPA pattern defines burnout.

This nuance demolishes a popular biohacking narrative. There is no tidy “cortisol number” that burnout reliably raises and that a supplement, adaptogen or peptide could push back to normal. The HPA axis is not broken in one direction; it is deregulated, and what re-regulates it is not a molecule aimed at cortisol or synapses but the removal of the chronic stressor and a return of normal sleep–wake and recovery cycles. Any compound — Dihexa included — that is pitched as “fixing burnout chemistry” is selling against the actual physiology.

From Cortisol to the Synapse: Hippocampus, CA3 and Synapse Loss

Here is where the stress story reaches the cellular level — and where it touches the synaptogenesis theme at the heart of this site. Sustained exposure to glucocorticoids does not just alter how you feel; it remodels stress-sensitive brain regions. Decades of work show that chronic cortisol exposure is associated with shrinkage of the hippocampus (critical for memory), a weakened prefrontal cortex (planning, working memory, focus) and an enlarged, more reactive amygdala (threat and emotion).

At the microscopic scale, the damage is to connections. Classic rodent studies found that weeks of elevated corticosterone produced substantial loss of synapses and dendritic retraction in the hippocampal CA3 region — one of the most reproducible findings in stress neuroscience — and chronic glucocorticoids consistently suppress adult hippocampal neurogenesis, the birth of new neurons. The structures most degraded by chronic stress are exactly the structures cognition depends on, which is why the resulting fog feels like a memory and focus problem: at the cellular level, it is one.

There is an important and hopeful flip side. Much of this remodelling is plastic and reversible: when the stressor lifts, dendrites can re-extend, neurogenesis can recover, and cognition tends to improve. The brain is not waiting for a synapse-building drug; it is waiting for the conditions — reduced load, restored sleep, real recovery — under which it rebuilds synapses itself. That single fact frames everything that follows about Dihexa.

The BDNF Link: How Chronic Stress Turns Down Plasticity

The molecular thread connecting cortisol, synapses and the case for any synaptogenic compound is brain-derived neurotrophic factor (BDNF) — the growth factor that supports neuronal survival, synaptic plasticity and long-term potentiation. Chronic stress turns BDNF down. Experimental work shows that chronic mild stress reduces activity-dependent BDNF transcription in the hippocampus, and that BDNF in the prefrontal cortex falls in stress-susceptible animals that develop anhedonia.

The link holds in humans under occupational stress. A study of workers exposed to occupational stress and suffering adjustment disorders found altered plasma BDNF and serum cortisol relationships — consistent with the idea that the same chronic-stress physiology that dysregulates cortisol also depresses the neurotrophic support synapses need. Low BDNF is, in effect, the brain dialling down its own capacity to remodel and learn precisely when it is most overwhelmed.

This is the hinge of the whole Dihexa conversation. If burnout fog is, at the cellular level, a low-BDNF, low-plasticity, synapse-poor state, then a compound that raises synaptogenic signalling is at least mechanistically on-topic. The decisive question — addressed next — is whether externally pushing synapse formation can correct a state whose cause is an ongoing overload, or whether it merely papers over a problem that only recovery resolves.

What Actually Reverses Burnout Fog: Recovery Is the Treatment

The most evidence-based statement in this entire review is the least glamorous: recovery is the treatment for burnout. Because the WHO defines burnout as the product of chronic workplace stress that has not been successfully managed, the interventions that work are the ones that change the stress–recovery balance. That means reducing or restructuring the workload, restoring sleep (see sleep and memory consolidation), taking genuine, uninterrupted time off, rebuilding boundaries and control over how work is done, and treating any co-existing depression or anxiety.

The encouraging corollary, grounded in the reversibility of stress-related brain changes, is that the cognitive symptoms usually lift as the system recovers. People who take a real break, fix their sleep and lighten the load typically find their focus and memory returning over weeks to months — the brain rebuilding the synapses chronic stress trimmed, without any pharmacological help. This is not a counsel of despair; it is the opposite. The thing that works is available to everyone and costs nothing but the hardest currency of all: changing the situation.

None of this is to romanticise “just rest.” For many people the load is structural — financial pressure, caring responsibilities, an unreasonable employer — and recovery requires practical and sometimes occupational-health or workplace intervention rather than willpower. But the direction of travel is clear and consistent across the evidence: burnout fog is solved by removing the cause and allowing repair, a process for which there is strong support and into which an unproven peptide adds nothing.

Where Dihexa Enters: The Synaptogenesis Hypothesis

Now the part readers come for. If chronic stress lowers BDNF, suppresses neurogenesis and thins synapses, is there a mechanistic case for a compound that pushes synaptogenesis back up by a different route? On paper, yes — and that is exactly why the question gets asked.

Dihexa (PNB-0408) is an orally active, blood-brain-barrier-penetrant peptide that acts as a positive modulator of hepatocyte growth factor (HGF) and its receptor c-Met. In preclinical work — most notably Benoist and colleagues (JPET, 2014) — activating HGF/c-Met drove synaptogenesis, the formation of new dendritic spines and functional synapses, and improved performance in memory tasks. The HGF/MET system also supports cerebrovascular health. Our mechanism of action page details the PI-3K/AKT and ERK signalling involved, and Dihexa vs BDNF unpacks the much-repeated “ten million times more potent than BDNF” claim — a slogan that needs careful reading, since it refers to a specific spine-promoting assay, not a real-world equivalence.

The convergence is genuinely neat. Burnout is, at the cellular level, a low-plasticity, BDNF-suppressed, synapse-poor state; HGF/c-Met is a pathway that, in animals, builds synapses. A reader can be forgiven for connecting the two and wondering whether Dihexa could short-circuit the recovery the brain is waiting to do anyway. The next section is where that hypothesis meets the hard logic of cause and effect.

Why “Pushing Synaptogenesis” Doesn't Fix an Overload Problem

The flaw in the synaptogenesis hypothesis for burnout is not the biology of Dihexa; it is the biology of burnout. In most of the conditions reviewed on this site, the “cause” of fog is something subtracted from the brain — a missing vitamin, a damaged region, a degenerative process. Burnout is different: the cause is something added — a sustained overload with insufficient recovery. The brain's plasticity machinery is not broken or depleted in a way a growth-factor drug replaces; it is being actively suppressed by an ongoing stressor. As long as that stressor and the missing recovery persist, the suppressive signal continues regardless of how hard you push synaptogenesis from the outside.

That mismatch creates a specific danger unique to burnout: masking. A research chemical that produced even a modest subjective lift could make someone feel able to keep going — to keep absorbing the overload that caused the burnout in the first place. Far from helping, that deepens the problem, because it removes the one signal (feeling unable to continue) that prompts the rest and recovery that actually work. It is the same trap people fall into with caffeine and stronger stimulants, only with an unproven peptide and an oncology-relevant pathway attached.

There is also no reason to expect the brain to rebuild the right synapses in response to an external synaptogenic push. Healthy plasticity is experience-dependent and tightly regulated; recovery rebuilds connections in a coordinated, use-driven way. Flooding the system with a synaptogenic signal while the stressor is still firing is not obviously beneficial and is entirely untested. The honest conclusion is that even granting Dihexa everything its mechanism promises, it is aimed at the wrong half of the equation: it might, in theory, nudge the “rebuild” side, while doing nothing about the “overload” side that is driving the whole problem.

The Stimulant Trap and the Masking Risk

Burnout has a long history of being met with chemistry rather than change, and it rarely ends well. The classic pattern is escalating reliance on caffeine, then sometimes prescription stimulants or off-label nootropics such as modafinil, to keep performing through exhaustion. Each works for a while by overriding the fatigue signal — and each, used to push through rather than to recover, tends to extend the period of overload and worsen the eventual crash. Sleep gets sacrificed, the HPA axis stays deregulated, and the underlying mismatch is never addressed.

An experimental synaptogenic peptide marketed for “cognitive recovery” slots neatly and dangerously into this pattern. The very framing — “rebuild your burned-out brain” — encourages people to treat burnout as a hardware fault to be patched rather than a life situation to be changed. Our broader cognitive enhancement overview makes the general point; in burnout it becomes acute, because the thing being masked is the body's protective insistence that you stop.

The cleaner way to think about it: in burnout, feeling foggy and depleted is not only a symptom to be abolished — it is partly information. The evidence-based response is to act on the information (reduce load, recover, seek help), not to chemically silence the messenger. That is the single biggest reason the editorial position here is that Dihexa belongs nowhere near a burnout protocol.

The Fosgonimeton Parallel and the Limits of Mechanism

For anyone still tempted to reason straight from “elegant mechanism” to “it should work,” the most important cautionary tale is fosgonimeton (ATH-1017), the closest clinical-stage relative of Dihexa. Fosgonimeton is a small-molecule positive modulator of the same HGF/MET system, developed by Athira Pharma and taken all the way into human Alzheimer's trials precisely because the synaptogenic, neurotrophic rationale looked so compelling. In 2024 its pivotal Phase 3 LIFT-AD trial missed its primary cognitive endpoint.

The lesson is not that HGF/c-Met is uninteresting — it plainly is — but that a beautiful mechanism, even one carried into rigorous, well-funded human trials, does not guarantee a clinical benefit. If the most advanced drug targeting this exact pathway could not beat placebo on cognition in its main indication, the prior for an unlicensed, never-trialled peptide producing reliable gains in burnout brain fog — a state defined by a situation rather than a target — should be set very low indeed. Mechanistic plausibility is a hypothesis, not a result. Our research and studies page keeps a running, honest account of where the Dihexa evidence actually stands.

Who Should Absolutely Not Consider Dihexa for Burnout

Some situations make experimentation clearly inappropriate, and burnout produces several. Anyone whose low mood has tipped into depression with hopelessness or thoughts of self-harm needs assessment and support — from a GP, or urgently from a service such as the Samaritans (116 123 in the UK) — not a research chemical; an unproven peptide in this situation can delay effective and potentially life-saving care. Anyone who is using a compound to keep pushing through rather than to recover is, by definition, using it against their own interests. Anyone who is pregnant or breastfeeding should not use Dihexa under any circumstances. And anyone with a personal or strong family history of cancer should weigh the c-Met / oncology caution very seriously, since c-Met is implicated in tumour growth and invasion — see our side effects and risks page.

This is the same conclusion reached across the lifestyle and drug-related reviews on this site: the more the underlying cause is a situation you can change, the weaker the argument for reaching past it toward an unproven compound. Burnout is the clearest example of all — a state whose definition is unmanaged chronic stress, and whose remedy is to manage it.

What the Evidence Actually Supports for Burnout Brain Fog in 2026

Pulling the threads together, the evidence-based approach in 2026 is clear and almost entirely unglamorous. Name it accurately — distinguish burnout from depression, anxiety, ME/CFS and the treatable medical causes of fog, with a GP's help. Reduce and restructure the load, using occupational-health or workplace support where the load is structural. Restore sleep and take real recovery time. Treat co-existing depression, anxiety, thyroid problems and nutritional deficiencies on their own merits. And give the brain the conditions under which its plasticity recovers, because the stress-related synaptic changes that cause the fog are, encouragingly, largely reversible.

What the evidence does not support is treating burnout fog as a deficiency to be supplemented away, or substituting a synaptogenic research chemical for the rest and recovery the syndrome actually requires. The HSE and Mental Health UK data make the scale of burnout undeniable; the cognition and stress-neuroscience literature make the brain effects real; and the same literature makes the recovery-based solution clear. Dihexa remains, for burnout as for every other indication on this site, a compound with an interesting mechanism and no human efficacy or safety data in the condition — and, uniquely here, a real risk of encouraging exactly the “push through” behaviour that makes burnout worse.

The Bottom Line in 2026

Burnout brain fog is real, common and — this is the hopeful part — largely reversible. The 2026 numbers show a workforce under unprecedented strain, the cognition research confirms that the fog is measurable rather than imagined, and the stress neuroscience traces it all the way down to suppressed BDNF, blunted neurogenesis and thinned-out synapses in the hippocampus and prefrontal cortex. It is genuinely tempting to look at that synaptic picture and reach for a synapse-building peptide.

But burnout is not a missing molecule; it is an overload with too little recovery, and the brain rebuilds itself once that balance is restored. Dihexa is mechanistically coherent and clinically unproven for burnout, and its biggest real-world risk is that it tempts people to keep pushing through instead of resting, getting help and changing what is making them ill. So the order of operations is the message: name the cause, reduce the load, restore sleep, treat co-existing depression or anxiety, and let recovery do the rebuilding. The peptide, if ever, comes a very long way after — and only inside the kind of trial that, for now, does not exist.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Anxiety & Chronic Stress (2026) — the closest companion review on the stress system and cognition.
• Dihexa for Depression & Low Mood (2026) — the condition burnout most overlaps with, and most often hides.
• Dihexa for ME/CFS (2026) — exhaustion and brain fog that can look like burnout but are not.
• Dihexa for Long COVID Brain Fog (2026) — another fatigue-plus-fog state in the differential.
• Dihexa, Sleep & Memory Consolidation (2026) — why restoring sleep is central to burnout recovery.
• Dihexa for Menopause & Perimenopause Brain Fog (2026) — overlapping fog in the same working-age population.
• Dihexa vs BDNF: What “10 Million Times More Potent” Actually Means — in-depth look at the synaptogenesis claim.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, cerebrovascular angiogenesis.
• Cognitive Enhancement Overview — the wider context on nootropics and “pushing through.”
• Modafinil — the stimulant most often reached for in burnout, and its limits.
• Side Effects & Risks — the general safety picture, including the c-Met caution.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• World Health Organization — Burn-out an “occupational phenomenon”: International Classification of Diseases (ICD-11 definition; three dimensions).
• Mental Health UK — The Burnout Report 2026 (YouGov, 4,502 adults; 91% high/extreme pressure; 20% took time off, 39% of 18–24s; high/increased workload the top driver; poor recovery support).
• Health and Safety Executive — Annual workplace health and safety statistics 2024/25 (964,000 workers; 52% of work-related ill health; 22.1 million working days lost).
• HSE — Work-related ill health and stress statistics, key figures for Great Britain.
• Cognitive function in clinical burnout: a systematic review and meta-analysis (Work & Stress, 2021) — executive function, attention and memory deficits.
• Cognitive functioning, sleep quality and work performance in non-clinical burnout: the role of working memory (2020).
• Functional connectivity in burnout syndrome: a resting-state EEG study (Frontiers in Human Neuroscience, 2025).
• Endocrine and immunological aspects of burnout: a narrative review (European Journal of Endocrinology, 2019) — HPA-axis dysregulation, blunted cortisol.
• Burnout is associated with reduced parasympathetic activity and reduced HPA axis responsiveness, predominantly in males (2015).
• Chronic mild stress modulates activity-dependent transcription of BDNF in rat hippocampal slices (2016).
• Reduction of BDNF in the prefrontal cortex and susceptibility to chronic stress-induced anhedonia (2023).
• Plasma BDNF and serum cortisol in workers exposed to occupational stress with adjustment disorders (2019).
• HGF and MET in brain development and neurological disorders (Frontiers in Cell and Developmental Biology, 2021).
• Benoist CC et al. (JPET, 2014) — Dihexa procognitive effects via HGF/Met and synaptogenesis.